Overview

Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis

Status:
Terminated

Trial end date:
2017-08-04

Target enrollment:

Participant gender:

Summary

This study will compare dalbavancin to standard of care (SOC) antibiotic therapy for the completion of therapy in patients with complicated bacteremia or infective endocarditis.

Phase:

Phase 2

Details

Lead Sponsor:

Allergan

Treatments:

Anti-Bacterial Agents
Antibiotics, Antitubercular
Dalbavancin
Teicoplanin